ArticleCureus2025

Optimizing Cardiovascular Outcomes in Type 2 Diabetes: Early Initiation of Dapagliflozin and Sitagliptin From a Cardiologist's Perspective.

K Jaishankar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.